Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis

References

• Samuelsson K, Jovanovic A, Egervall K, et al. Hereditary transthyretin amyloidosis in Sweden: comparisons between a non-endemic and an endemic region. Amyloid. 2022;29(4):220–227. doi: 10.1080/13506129.2022.2065191.
   PubMed Web of Science ®Google Scholar
• Conceição I, González-Duarte A, Obici L, et al. Red-flag symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5–9. doi: 10.1111/jns.12153.
   PubMed Web of Science ®Google Scholar
• Hazenberg BPC. Amyloidosis: a clinical overview. Rheum Dis Clin North Am. 2013;39(2):323–345. doi: 10.1016/j.rdc.2013.02.012.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. doi: 10.1056/NEJMoa1716153.
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–2667. doi: 10.1001/jama.2013.283815.
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31. doi: 10.1056/NEJMoa1716793.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802–2814. doi: 10.1007/s00415-013-7051-7.
   PubMed Web of Science ®Google Scholar
• Adams D, Suhr OB, Hund E, et al. First european consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29 Suppl 1(Suppl 1):S14–S26. doi: 10.1097/WCO.0000000000000289.
   PubMedGoogle Scholar
• Obici L, Kuks JB, Buades J, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29 Suppl 1(Suppl 1):S27–S35. doi: 10.1097/WCO.0000000000000290.
   PubMedGoogle Scholar
• Adams D, Ando Y, Beirão JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021;268(6):2109–2122. doi: 10.1007/s00415-019-09688-0.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Davies JL, Litchy WJ, et al. Longitudinal assessment of diabetic polyneuropathy using a composite score in the rochester diabetic neuropathy study cohort. Neurology. 1997;49(1):229–239. doi: 10.1212/wnl.49.1.229.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Kennedy WR, Kesserwani H, et al. Limitations of quantitative sensory testing when patients are biased toward a bad outcome. Neurology. 1998;50(5):1213–1213. doi: 10.1212/wnl.50.5.1213.
   PubMed Web of Science ®Google Scholar
• Casellini CM, Parson HK, Richardson MS, et al. Sudoscan, a noninvasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction. Diabetes Technol Ther. 2013;15(11):948–953. doi: 10.1089/dia.2013.0129.
   PubMed Web of Science ®Google Scholar
• Low PA, Tomalia VA, Park KJ. Autonomic function tests: some clinical applications. J Clin Neurol. 2013;9(1):1–8. doi: 10.3988/jcn.2013.9.1.1.
   PubMed Web of Science ®Google Scholar
• Luigetti M, Romozzi M, Bisogni G, et al. hATTR pathology: nerve biopsy results from italian referral centers. Brain Sci. 2020;10(11):780. doi: 10.3390/brainsci10110780.
   PubMed Web of Science ®Google Scholar
• Fernandes A, Coelho T, Rodrigues A, et al. Clinicopathological correlations of sural nerve biopsies in TTR Val30Met familial amyloid polyneuropathy. Brain Commun. 2019;1(1):fcz032.
   PubMedGoogle Scholar
• Masuda T, Ueda M, Misumi Y, et al. Reduced intraepidermal nerve fibre density in patients with hereditary transthyretin amyloidosis. Amyloid. 2019;26(sup1):79–80. doi: 10.1080/13506129.2019.1583198.
   PubMed Web of Science ®Google Scholar
• Ebenezer GJ, Liu Y, Judge DP, et al. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Ann Neurol. 2017;82(1):44–56. doi: 10.1002/ana.24972.
   PubMed Web of Science ®Google Scholar
• Leonardi L, Adam C, Beaudonnet G, et al. Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis. Eur J Neurol. 2022;29(5):1477–1487. doi: 10.1111/ene.15268.
   PubMed Web of Science ®Google Scholar
• Leonardi L, Galosi E, Vanoli F, et al. Skin biopsy and quantitative sensory assessment in an italian cohort of ATTRv patients with polyneuropathy and asymptomatic carriers: possible evidence of early non-length dependent denervation. Neurol Sci. 2022;43(2):1359–1364. doi: 10.1007/s10072-021-05434-5.
   PubMed Web of Science ®Google Scholar
• Kapoor M, Foiani M, Heslegrave A, et al. Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J Peripher Nerv Syst. 2019;24(4):314–319. doi: 10.1111/jns.12350.
   PubMedGoogle Scholar
• Maia LF, Maceski A, Conceição I, et al. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid. 2020;27(2):97–102. doi: 10.1080/13506129.2019.1708716.
   PubMed Web of Science ®Google Scholar
• Louwsma J, Brunger AF, Bijzet J, et al. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid. 2021;28(1):50–55. doi: 10.1080/13506129.2020.1815696.
   PubMed Web of Science ®Google Scholar
• Loser V, Benkert P, Vicino A, et al. Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin-related amyloidosis—a Swiss reference center experience. J Peripher Nerv Syst. 2023;28(1):86–97. doi: 10.1111/jns.12524.
   PubMed Web of Science ®Google Scholar
• Luigetti M, Di Paolantonio A, Guglielmino V, et al. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience. Neurol Sci. 2022;43(4):2845–2848. doi: 10.1007/s10072-021-05850-7.
   PubMed Web of Science ®Google Scholar
• Ticau S, Sridharan GV, Tsour S, et al. Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology. 2021;96(3):E412–E422. doi: 10.1212/WNL.0000000000011090.
   PubMed Web of Science ®Google Scholar
• Ticau S, Aldinc E, Polydefkis M, et al. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study. Amyloid. 2023;31(1):1–11. doi: 10.1080/13506129.2023.2232520.
   PubMedGoogle Scholar
• Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8(1):31. doi: 10.1186/1750-1172-8-31.
   PubMed Web of Science ®Google Scholar
• Van Gameren II, Hazenberg BPC, Bijzet J, et al. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for destecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006;54(6):2015–2021. doi: 10.1002/art.21902.
   PubMedGoogle Scholar
• Schubert CR, Paulsen AJ, Pinto AA, et al. Effect of long-term storage on the reliablity of blood biomarkers for alzheimer’s disease and neurodegeneration. J Alzheimers Dis. 2022;85(3):1021–1029. doi: 10.3233/JAD-215096.
   PubMed Web of Science ®Google Scholar
• Van Lierop ZYGJ, Verberk IMW, Van Uffelen KWJ, et al. Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1. Clin Chem Lab Med. 2022;60(6):842–850. doi: 10.1515/cclm-2022-0007.
   PubMed Web of Science ®Google Scholar
• Vermunt L, Otte M, Verberk IMW, et al. Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface. Ann Clin Transl Neurol. 2022;9(11):1832–1837. doi: 10.1002/acn3.51676.
   PubMed Web of Science ®Google Scholar
• Benkert P, Meier S, Schaedelin S, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022;21(3):246–257. doi: 10.1016/S1474-4422(22)00009-6.
   PubMed Web of Science ®Google Scholar
• Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577–589. doi: 10.1038/s41582-018-0058-z.
   PubMed Web of Science ®Google Scholar
• Akamine S, Marutani N, Kanayama D, et al. Renal function is associated with blood neurofilament light chain level in older adults. Sci Rep. 2020;10(1):20350. doi: 10.1038/s41598-020-76990-7.
   PubMed Web of Science ®Google Scholar
• Romano A, Primiano G, Antonini G, et al. Serum neurofilamant light chain: a promising biomarker for hereditary transthyretin amyloidosis? Eur J Neurol. 2024;31(1):e16070.
   PubMed Web of Science ®Google Scholar
• Berends M, Nienhuis HLA, Brunger AF, et al. Serum neurofilament light chain (sNfL) in relation to myocardial sympathetic neuronal damage based on 123I-meta-iodobenzylguanidine (MIBG) scintigraphy in hereditary transthyretin (ATTRv) amyloidosis. Paper presented at: Cardiovascular metabolism, innervation and perfusion. The Annual European Association of Nuclear Medicine; 2022 Oct 15–19; Barcelona, Spain.
   Google Scholar
• Groothof D, Bijzet J, van den Berg MP, et al. Diagnostic value of subcutaneous abdominal fat tissue aspirates in cardiac amyloidosis. Poster presented at: Cardiac amyloidosis and other forms. The XVII International Symposium On Amyloidosis; 2020 Sep 14–18; Tarragona, Spain.
   Google Scholar
• Coppens S, Lehmann S, Hopley C, et al. Neurofilament-light, a promising biomarker: analytical, metrological and clinical challenges. Int J Mol Sci. 2023;24(14):11624. doi: 10.3390/ijms241411624.
   PubMed Web of Science ®Google Scholar
• Polydefkis M, Aldinc E, Nienhuis H, et al. NfL levels significantly decrease in response to treatment with patisiran or vutrisiran in hATTR amyloidosis with polyneuropathy. Poster presented at: Global neurology. 147th annual meeting American Neurological Association; 2022 Oct 22–25; Chicago, IL.
   Google Scholar
• Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29(3):143–155. doi: 10.1080/13506129.2022.2052838.
   PubMed Web of Science ®Google Scholar
• Buxbaum JN. Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials. Amyloid. 2019;26(2):55–65. doi: 10.1080/13506129.2019.1575201.
   PubMed Web of Science ®Google Scholar